Tag: breakthrough therapy designation

Omalizumab + OIT

Clinical Trial to Evaluate Experimental Treatment in People Allergic to Multiple...

NIH and partners to assess whether Omalizumab can reduce allergic reactions.
Xolair (omalizumab)

FDA Grants Xolair Breakthrough Therapy Designation for Food Allergies

Breakthrough Therapy Designation was granted on the basis of data from seven clinical studies assessing the efficacy and safety of Xolair against a range of food allergens including peanut, milk, egg and others.
AR101

Aimmune Begins Patient Enrollment for Phase III Clinical Trial of Peanut...

First of 440 patients enrolled in study of AR101.

Breakthrough Food Allergy Therapies and the Big Business Behind Them

What it means to be a breakthrough therapy, who is developing them, how they work, and the (big) business drivers behind them.

Connect with Us

39,150FansLike
770FollowersFollow
2,714FollowersFollow
5,529FollowersFollow
40SubscribersSubscribe